ICYMI: Bimekizumab is Coming…in Third Place Of the many exciting advancements for patients with psoriatic arthritis at ACR23 one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. https://t.co/rhyEuyCjQI https://t.co/vbRs2144We